ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Abeona Therapeutics Inc

Abeona Therapeutics Inc (ABEO)

4.29
-0.02
(-0.46%)
Closed May 22 4:00PM
4.29
0.00
( 0.00% )
Pre Market: 4:04AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
4.29
Bid
4.10
Ask
5.30
Volume
-
0.00 Day's Range 0.00
2.83 52 Week Range 9.01
Market Cap
Previous Close
4.29
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
731,490
Shares Outstanding
24,773,317
Dividend Yield
-
PE Ratio
-1.96
Earnings Per Share (EPS)
-2.19
Revenue
4.57M
Net Profit
-54.19M

About Abeona Therapeutics Inc

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Abeona Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ABEO. The last closing price for Abeona Therapeutics was $4.29. Over the last year, Abeona Therapeutics shares have traded in a share price range of $ 2.83 to $ 9.01.

Abeona Therapeutics currently has 24,773,317 shares outstanding. The market capitalization of Abeona Therapeutics is $106.28 million. Abeona Therapeutics has a price to earnings ratio (PE ratio) of -1.96.

ABEO Latest News

Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress

BLA resubmission anticipated in second half of 2024 Closed $75 million underwritten offering in May, extending expected cash runway into 2026 CLEVELAND, May 15, 2024 (GLOBE NEWSWIRE) -- Abeona...

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, May 07, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...

Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

CLEVELAND, May 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) (“Abeona” or the “Company”) today announced the pricing of an underwritten offering of 12,285,056 shares of...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.54-11.18012422364.834.834.224889234.41302022CS
41.1235.33123028393.175.113.0510852584.187876CS
12-2.67-38.36206896556.969.013.057314905.15624069CS
260.194.634146341464.19.013.055009885.23860506CS
521.0934.06253.29.012.833191984.96249597CS
1562.72173.2484076431.579.010.13038730001.38453612CS
260-2.61-37.82608695656.99.010.130312192861.97078005CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ZCARZoomcar Holdings Inc
$ 0.50
(138.10%)
4.26M
ASTIAscent Solar Technologies Inc
$ 0.2393
(82.12%)
41.7M
GWAVGreenwave Technology Solutions Inc
$ 0.108
(37.06%)
67.1M
NCPLNetcapital Inc
$ 0.20
(31.58%)
17.53M
ISPCiSpecimen Inc
$ 0.3906
(23.02%)
9.72M
MGOLMGO Global Inc
$ 0.6982
(-39.81%)
1.09M
AKTSAkoustis Technologies Inc
$ 0.2163
(-31.36%)
5.07M
RDZNRoadzen Inc
$ 3.20
(-18.58%)
4.43k
MGRXMangoceuticals Inc
$ 0.3818
(-17.00%)
147.33k
DMTKDermTech Inc
$ 0.35
(-16.67%)
42.68k
GWAVGreenwave Technology Solutions Inc
$ 0.108
(37.06%)
67.1M
ASTIAscent Solar Technologies Inc
$ 0.2393
(82.12%)
41.7M
NCPLNetcapital Inc
$ 0.20
(31.58%)
17.53M
ISPCiSpecimen Inc
$ 0.3906
(23.02%)
9.72M
BRSHBruush Oral Care Inc
$ 0.1562
(5.68%)
9.53M

ABEO Discussion

View Posts
Monksdream Monksdream 3 weeks ago
ABEO under $5
👍️0
Awl416 Awl416 3 weeks ago
Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
👍️0
Monksdream Monksdream 3 months ago
ABEO new 52+week high
👍️0
Monksdream Monksdream 3 months ago
ABEO new 52 week high
👍️0
Monksdream Monksdream 3 months ago
ABEO new 52 week high
👍️0
Monksdream Monksdream 3 months ago
ABEO new 52 week high
👍️0
Monksdream Monksdream 3 months ago
ABEO new 52 week high
👍️0
Monksdream Monksdream 3 months ago
ABEO new 52 week high
👍️0
Joelzee Joelzee 12 months ago
Of course this goes up after I close my position. ??
👍️0
Invest-in-America Invest-in-America 2 years ago
You gots me CONFUSED, Young Lady!! YES, I indeed DID post over there --- which YOU should have IGNORED in the first place!! WHATEVER!!! Bottom line???? GO-GO-GO-BABL and HPCO!!! Those two are where I am 'losing-my-shirt' right now!!

👍️0
gail gail 2 years ago
you already posted there silly, so i replied to you there in pm. and yes, i know you cant pm back anymore.
👍️0
Invest-in-America Invest-in-America 2 years ago
O.K., I'll take a look at THAT one right now.
👍️0
gail gail 2 years ago
i found it on my…

..

own but got back out, its junk, lol. i was replying to you on the other stock admp.
👍️0
Invest-in-America Invest-in-America 2 years ago
ABEO: It's pronounced like, "ABALONE" (that Fish thing)!!

PS: I got your PM, but can't reply to it. Bottom line, do NOT "invest" in ANY of my stock picks!! (Which is great advice for ME, too!!)

👍️0
gail gail 2 years ago
can anyone pronounce …

..

this?

Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
👍️0
gail gail 2 years ago
nice pop in overnight trading. lets see what she does today.
👍️0
gail gail 2 years ago
quiet board but this stock is on the move! grabbed a few today.
👍️0
stock1ace1 stock1ace1 2 years ago
$3.69 news data coming within a month
👍️0
stock1ace1 stock1ace1 2 years ago
Topline data from the Phase 3 VIITAL™ study of EB-101 in RDEB is on track for late third quarter to early fourth quarter of 2022 upon completion of the last patient monitoring visit, which is expected by mid-September.
👍️0
stock1ace1 stock1ace1 2 years ago
Buying $3.01 phase 3 data due anyday 3 mil o/s 3 mill float



Topline data from the Phase 3 VIITAL™ study of EB-101 in RDEB is on track for late third quarter to early fourth quarter of 2022 upon completion of the last patient monitoring visit, which is expected by mid-September.
👍️0
INFINITI INFINITI 2 years ago
We need to get this over $1
👍️0
INFINITI INFINITI 2 years ago
Let’s goooo$$$$
👍️0
INFINITI INFINITI 2 years ago
Looks good here
👍️0
saj saj 2 years ago
ABEO .35 +7%
👍️0
ClayTrader ClayTrader 3 years ago
* * $ABEO Video Chart 02-25-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
jerseyboy jerseyboy 3 years ago
They are MBIO, SIOX, and GTHX. GTHX will be the most successful of the three, as they have a recently-approved drug that will change the face of the use of chemotherapy. It is still amazingly cheap relative to its value, and is an easy three-bagger within at most two years, and probably before that.
👍️0
CyrusDaVirus CyrusDaVirus 3 years ago
Which are those 3?
👍️0
jerseyboy jerseyboy 3 years ago
I had to say goodbye to Abeona earlier this week when its price rose above my basis, as I swore to myself that I would do so if it ever recovered from its rapid decline to $1.00. I split it among three other biopharmas which I think have more immediate prospects of bringing their pipelines to revenue-generating fruition. This is a good company, but I think bringing their pipeline to revenue-generating fruition will take awhile from this point. Michael Amoroso should get a lot of credit for what he's done so far as Abeona's leader. Good luck to all who invest here. You could find a lot worse companies in which to invest.
👍️0
jerseyboy jerseyboy 3 years ago
I like what they're doing and obviously also like the share price movement today. Michael Amoroso should get a lot of credit for the way he was able to turn this situation around.
👍️0
jerseyboy jerseyboy 3 years ago
Apparently from the news today Michael Amoroso does know what he is doing. I had a feeling that they were down but not out. I have a good feeling about the gradual and successful development of their pipeline.
👍️0
Golden Cross Golden Cross 3 years ago
Heck ya
👍️0
jerseyboy jerseyboy 3 years ago
The share price is certainly showing a nice steady increase.
👍️0
Golden Cross Golden Cross 3 years ago
Chart looks to be a nice steady incline here
👍️0
jerseyboy jerseyboy 3 years ago
With today's advance, this has almost doubled from the level to where it fell when the CEO and five directors simultaneously resigned. Hopefully the price advance reflects positive things that Michael Amoroso is doing to develop the company. I've held all my shares through the downturn, and have confidence in his background and the company's pipeline.
👍️0
Golden Cross Golden Cross 3 years ago
strong chart here
👍️0
jerseyboy jerseyboy 3 years ago
I feel like people are sleeping on this one. It was a major shock from which to recover to have the CEO and half of the board resign, but I think Michael Amoroso knows what he is doing and is doing a good job in moving the company forward, and I believe that there is good long-term potential here.
👍️0
railrider railrider 3 years ago
News just out spiking up on it
👍️0
jerseyboy jerseyboy 3 years ago
Wow - nice jump today - up 17%! It's still a long way to my basis of $2.98 per share, but something is afoot here with the kind of volume we saw today.
👍️0
jerseyboy jerseyboy 3 years ago
Nice jump today and up over 50% from its low. Let's hope Michael Amoroso can do something here with the assets and the pipeline. He's certainly got the background to be able to bring it forward.
👍️0
ClayTrader ClayTrader 4 years ago
* * $ABEO Video Chart 11-11-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
whytestocks whytestocks 4 years ago
Breaking News: $ABEO What Are The Best Penny Stocks To Buy Now? 3 Biotech Stocks To Watch

3 Biotech Penny Stocks to Watch in 2020 Biotech penny stocks have become some of the most popular choices for all types of investors. Both institutional and retail investors have been working to seek gains in the biotech industry. Since the beginning of the year, investors have turn...

Got this from ABEO - What Are The Best Penny Stocks To Buy Now? 3 Biotech Stocks To Watch
👍️0
realfast95 realfast95 4 years ago
2x813008 shares free options for 1 year, to two directors
WTF
👍️0
realfast95 realfast95 4 years ago
On September 17, 2020, Abeona Therapeutics Inc. (the “Company”) had filed a Current Report on Form 8-K reporting that Steven H. Rouhandeh had notified the Company of his resignation from the Board of Directors (the “Board”), effective September 30, 2020. On September 30, 2020, Mr. Rouhandeh rescinded his resignation from the Board, and the Board accepted his rescission of resignation. Also on September 30, 2020, the Board voted unanimously to elect Mr. Rouhandeh as Chairman of the Board. Mr. Rouhandeh will not be taking on any additional compensation as Chairman other than what he was already receiving as a non-employee director, which such compensation is disclosed in the Company’s proxy statement filed on April 10, 2020.

8k
👍️0
whytestocks whytestocks 4 years ago
BREAKING NEWS: $ABEO Abeona Therapeutics' Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan

Steven H. Rouhandeh Appointed as Chairman of the Board of Directors Jefferies LLC R etained as F inancial A dvisor to A ssist with the R eview of S trategic O ptions NEW YORK and CLEVELAND, Oct. 06, 2020 (GLOBE NEWSWI...

Find out more ABEO - Abeona Therapeutics' Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan
👍️0
realfast95 realfast95 4 years ago
Steven Rouhandeh
Founder,Chairman and Chief Investment Officer at SCO Capital Partners
Location: United States

Mr. Steven H. Rouhandeh, also known as Steve, J.D., is the Founder of SCO Capital Partners, LLC and has been its Chairman and Chief Investment Officer since 1997. Mr. Rouhandeh is the Founder of SCO Financial Group, LLC and serves as its Chairman. He has been an Executive Chairman at PlasmaTech Biopharmaceuticals, Inc. since March 4, 2008 and has been its Principal Executive Officer since January 1, 2015.
👍️0
realfast95 realfast95 4 years ago

Abeona Therapeutics’ Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Lead...
October 06 2020 - 04:01PM

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that its Board of Directors has formed a Special Committee to oversee and advise the executive leadership team on the operations of the Company, leveraging the respective medical, business development and financial expertise of its members. The Special Committee, which consists of current board members, is also working closely with the executive leadership team to develop the Company’s strategic direction and leadership plan as it continues to advance its clinical programs toward providing novel gene and cell therapies to patients who currently have no approved treatment options. The Company also announced the appointment of Steven H. Rouhandeh as Chairman of its Board of Directors.

Strategic Review

Abeona has retained Jefferies LLC as its financial advisor to assist with the review of strategic options focused on advancing the Company’s mission and maximizing stakeholder value. There can be no assurance this strategic review will result in the completion of any particular course of action. There is no defined timeline for completion of the review process and the Company does not intend to comment further unless a specific initiative is approved by the Board of Directors, the review process is concluded, or it is otherwise determined that other disclosure is appropriate.
👍️0
realfast95 realfast95 4 years ago
Abeona Therapeutics selloff yesterday an overreaction, says B. Riley FBR 08:00 ABEO B. Riley FBR analyst Justin Zelin lowered the firm's price target on Abeona Therapeutics to $2 from $5 and reiterates a Buy rating on the shares. The company's assets, including manufacturing infrastructure, are worth more than the market's current valuation following yesterday's 41% selloff, Zelin tells investors in a research note. However, to reflect reduced transparency into Abeona's leadership and strategy Zelin lowered his probability of success for lead asset EB-101 from 65% to 50% and from 20% to 15% for AB-102 and AB-101. Nonetheless, the analyst views yesterday's pullback as overreaction and continues to see upside in the shares.

Read more at:
https://thefly.com/n.php?id=3167175
👍️0
RJ Trotts RJ Trotts 4 years ago
picked up some shares for a bounce here
👍️0
willlbone willlbone 4 years ago
The rats are leaving a burning ship.
👍️0
realfast95 realfast95 4 years ago
Press Release: Abeona Therapeutics Announces Leadership and Board Transitions
9:27 am ET September 28, 2020 (Dow Jones) Print

Abeona Therapeutics Announces Leadership and Board Transitions

NEW YORK and CLEVELAND, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced changes in its executive leadership and Board of Directors. João Siffert, M.D. resigned from his positions as CEO, Head of Research and Development, and Chief Medical Officer, as well as member of the Board of Directors, on September 23, 2020. On September 27, 2020, Brian Pereira, M.D., Stefano Buono, Stephen B. Howell, M.D., George Migausky and Shawn Tomasello each announced that they had stepped down from the Board, effective immediately. No director gave any reason for their resignation and no director indicated any disagreements with the Company.

The Company is reviewing and exploring all strategic options and alternatives focused on advancing the Company's mission and maximizing stakeholder value, including the sale of some or all of its assets or sale of the Company. There can be no assurance this strategic review will result in the completion of any particular course of action. There is no defined timeline for completion of the review process.
👍️0

Your Recent History

Delayed Upgrade Clock